Dr. Anthony Reder has a 30-year interest in multiple sclerosis.
He has coauthored over 150 papers, plus many abstracts and presentations, on the immunology and treatment of multiple sclerosis. His primary research interests are in the interaction between the central nervous system (CNS) and the cellular immune system, and in how the brain and immune system are altered by the drugs we use to treat MS. Professor Reder has an active lab studying many facets of the immune disruption in MS, and also the mechanism of action of interferon-beta, the most widely-used treatment for MS. They have recently found that there is a defect in the interferon signaling pathway in lymphocytes from progressive forms of MS. This may be why some patients with progressive MS do not respond clinically to interferon therapy.
Dr. Reder and other faculty members at the University of Chicago have participated in the development of multiple new treatments for MS over 30 years. These include the first biological therapy for MS, interferon-beta, plus other interferons, glatiramer (Copaxone), natalizumab (Tysabri), rituximab (Rituxan), ocrelizumab (Ocrevus), estriol (the pregnancy hormone), and FTY720/fingolimod (Gilenya); plus drugs for pain in MS and trigeminal neuralgia, such as misoprostol. He has also evaluated patients treated with IFN-b, 21 years after the original pivotal trial, and found effects of statins and vitamin D on IFN efficacy. Current clinical trials include promising new drugs for neuromyelitis optica (NMO) and progressive MS.
He has trained a number of excellent MS fellows, funded by the US National MS Society. Prior fellows, Adil Javed, and as of Aug 1, 2018, Veronica Cipriani, are now on faculty at the U of Chicago. Dr. Javed defined a new variant of MS, CNS Sjögren’s disease, which requires different treatments than conventional MS.
Dr. Reder is also kind to puppies.

Dr. Anthony Reder has a 30-year interest in multiple sclerosis.
He has coauthored over 150 papers, plus abstracts and presentations, on multiple sclerosis and animal models of MS. His primary research interests are in the interaction between the central nervous system (CNS) and the cellular immune system, and in how the brain and immune system are altered by the drugs we use to treat MS. Professor Reder has an active lab studying many facets of the immune disruption in MS, and also the mechanism of action of interferon-beta, the most widely-used treatment for MS. They have recently found that there is a defect in the interferon signaling pathway in lymphocytes from progressive forms of MS. This may be why some patients with progressive MS do not respond clinically to interferon therapy.
Dr. Reder and other faculty members at the University of Chicago have participated in the development of multiple new treatments for MS. These include the first biological therapy for MS, interferon-beta, plus other drugs including glatiramer (Copaxone), natalizumab (Tysabri), rituximab, ocrelizumab, estriol (the pregnancy hormone), and FTY720/fingolimod (Gilenya), plus drugs for pain in MS such as misoprostol. He has also evaluated IFN-? patients 21 years after the original pivotal trial, the effects of statins and vitamin D on IFN efficacy, Current clinical trials include promising new drugs for neuromyelitis optica (NMO) and progressive MS.
He has trained a number of excellent MS fellows, funded by the US National MS Society. Prior fellows, Adil Javed, and as of Aug 1, Veronica Cipriani, are now on faculty at the U of Chicago. Dr. Javed defined a new variant of MS, CNS Sjögren’s disease, which requires different treatments than conventional MS.
Dr. Reder is also kind to puppies.